Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
Authors' conclusion
ABA monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of ABA appear to be independent of MTX coadministration.
Study context
- Population
- Children with polyarticular-course JIA (aged 2–17 years) in whom prior methotrexate (MTX) use was ineffective or not tolerated
- Participants
- 310 vs 99
- Comparison
- Abatacept + MTX vs abatacept monotherapy
- ABA + MTXn = 310
- ABA monotherapyn = 99reference
Methodological detailsstratified by MTX use and prior biologic use
- Stratified by MTX use and prior biologic use
Primary result
As reported in the abstract
Efficacy responses (JIA-ACR and JADAS27-CRP) · 2 years
- Efficacy responses similar between ABA + MTX and ABA monotherapy and persisted over 2 years
- Post hoc analysis
Further findings
Clinical response rates by prior biologic use
- Similar in biologic-naïve patients and prior biologic users, independent of MTX use
Pharmacokinetics
- Similar minimum steady-state trough ABA concentrations between studies
- Baseline MTX did not influence ABA clearance and was not a significant predictor of JIA-American College of Rheumatology (JIA-ACR) responses
Original publication
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. J Rheumatol. Published 15 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →